DeFord John A 4

What Happened John A. DeFord, a director of Maravai LifeSciences Holdings, Inc. (MRVI), was granted 46,293 restricted stock units (RSUs) on May 26, 2026. The award was reported on a Form 4 filed May 28, 2026. The RSUs were issued at $0.00 (no purchase price) and represent a future right to receive common shares if and when the units vest.

Key Details

• Transaction type: Award/Grant (code A) of 46,293 RSUs on 2026-05-26. Acquisition price reported: $0.00. Reported value on the Form 4: $0.
• Vesting: Per filing footnote, RSUs vest in full upon the earlier of one year from grant (May 26, 2027) or the date of the 2027 Maravai annual meeting of stockholders.
• Shares owned after transaction: Not specified in the provided filing summary.
• Filing timeliness: Form 4 filed two days after the grant (reported May 28, 2026 for a 2026-05-26 transaction) — appears timely; no late-filing flag noted.
• Nature of award: RSUs are a form of equity compensation that convert to shares upon vesting; this is a grant/compensation event, not an open-market purchase or sale.

Context RSU grants are common compensation for executives and directors and signal company compensation decisions rather than an outright market bet by the insider. They do not represent immediately tradable shares until they vest and are delivered. This filing documents the award and its vesting terms; it does not indicate any immediate cash proceeds or sale by the insider.